Novial (Desogestrel, Ethinylestradiol)

The two hormones in Novial suppress the release of luteinizing hormone and follicle‑stimulating hormone from the pituitary gland, which stops ovulation. Desogestrel also thickens cervical mucus, while ethinylestradiol modifies the endometrium, making it less suitable for implantation.

The dosing regimen for Novial is determined by the prescribing healthcare professional. Typically, it is taken as a daily tablet according to a specific cycle, but the exact schedule and number of tablets should follow the prescriber’s instructions.

Novial is intended for use only when pregnancy is not desired. It should not be started during an existing pregnancy, and women who become pregnant should discontinue use. Safety during breastfeeding has not been fully established, so a healthcare provider should be consulted.

To order Novial, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Novial contains the same hormone combination (desogestrel and ethinylestradiol) found in many other combined oral contraceptives. Its efficacy, safety profile and side‑effect spectrum are comparable to other products in the class, with differences mainly in dosage strengths and brand‑specific excipients.

Novial tablets should be stored at ambient temperature, below 25 °C, in their original packaging. They must be kept away from moisture, direct sunlight and excessive heat to maintain potency throughout the shelf life.

Novial is taken orally as a tablet, usually once daily at the same time each day. The typical regimen follows a 21‑day active tablet phase followed by a 7‑day placebo or hormone‑free interval, but patients should follow the schedule prescribed by their clinician.

The most serious risks include thromboembolic events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. These risks are higher in women who smoke, are over 35, or have a history of clotting disorders, and they require immediate medical attention if symptoms appear.

Novial is contraindicated in women with a history of thromboembolic disease, active liver disease, known or suspected breast cancer, uncontrolled hypertension, or those who are pregnant. It should also be avoided by smokers over 35 years of age and by anyone taking interacting medications without medical supervision.